Health Care [ 11/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer.
The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program.
Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 28, 25 | -0.54 Increased by +37.21% | -0.70 Increased by +23.30% |
| Nov 13, 24 | -0.59 Increased by +10.61% | -0.59 Increased by +0.24% |
| Aug 13, 24 | -0.52 Increased by +17.46% | -0.57 Increased by +8.77% |
| May 14, 24 | -0.73 Decreased by -25.86% | -0.84 Increased by +13.10% |
| Mar 28, 24 | -0.86 Decreased by -7.50% | -0.73 Decreased by -17.81% |
| Nov 9, 23 | -0.66 Decreased by -29.41% | -0.71 Increased by +7.04% |
| Aug 11, 23 | -0.63 | -0.65 Increased by +3.08% |
| May 9, 23 | -0.58 | -0.60 Increased by +3.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -22.83 M Decreased by -18.59% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -22.44 M Decreased by -55.13% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -18.80 M Decreased by -35.10% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -16.49 M Decreased by -48.27% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.88 M Increased by +N/A% | -19.25 M Decreased by -143.30% | Decreased by -1.02 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -14.47 M Decreased by -64.00% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -13.91 M Decreased by -143.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -11.12 M Decreased by -53.83% | Decreased by N/A% Decreased by N/A% |